Top 10 Drugs by Worldwide Sales in 2025
The pharmaceutical market in 2025 continues to be led by innovative therapies addressing cancer, metabolic diseases, autoimmune conditions, and chronic illnesses. Below is an updated overview of the top 10 drugs by projected global sales in 2025.
GLP-1 receptor agonists dominate the metabolic therapy segment with four drugs in the top 10: Ozempic and Wegovy (both semaglutide-based), Mounjaro and Zepbound (tirzepatide-based). These drugs are primarily used for type 2 diabetes and obesity management, reflecting the growing global focus on metabolic diseases (2, 5).
.png)
Dupixent (dupilumab) and Skyrizi (risankizumab) are prominent autoimmune therapies, addressing conditions like atopic dermatitis, asthma, psoriasis, and Crohn’s disease, maintaining strong market positions with combined sales near $30 billion (2, 5).
Eliquis (apixaban), an anticoagulant, continues to be a top seller due to its widespread use in stroke prevention for atrial fibrillation and treatment of thromboembolic disorders (3, 5).
HIV treatment Biktarvy and cancer drug Darzalex also maintain high sales, each expected around $13 billion, underscoring continued demand in infectious disease and oncology (5).
Highlights and Market Trends
Keytruda (Pembrolizumab) remains the global leader in drug sales with projected revenues exceeding $31 billion in 2025. This cancer immunotherapy has expanded to over 40 approved indications since its launch in 2014, including multiple cancer types, driving strong sales growth. Merck reported $21.6 billion in sales for the first three quarters of 2024, an 18% increase year-on-year (2, 5, 7) .GLP-1 receptor agonists dominate the metabolic therapy segment with four drugs in the top 10: Ozempic and Wegovy (both semaglutide-based), Mounjaro and Zepbound (tirzepatide-based). These drugs are primarily used for type 2 diabetes and obesity management, reflecting the growing global focus on metabolic diseases (2, 5).
.png)
Dupixent (dupilumab) and Skyrizi (risankizumab) are prominent autoimmune therapies, addressing conditions like atopic dermatitis, asthma, psoriasis, and Crohn’s disease, maintaining strong market positions with combined sales near $30 billion (2, 5).
Eliquis (apixaban), an anticoagulant, continues to be a top seller due to its widespread use in stroke prevention for atrial fibrillation and treatment of thromboembolic disorders (3, 5).
HIV treatment Biktarvy and cancer drug Darzalex also maintain high sales, each expected around $13 billion, underscoring continued demand in infectious disease and oncology (5).
Comments